Home › Therapeutic areas › Oncology › Pancreatic Cancer

Pancreatic Cancer (27 companies)

Companies with an active program in Pancreatic Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 1 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 1 Phase 2 $15.2M 4
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
DRTS Alpha Tau Medical Oncology 1 Phase 2 $1.12B 6
RCUS Arcus Biosciences DermatologyImmunology+1 1 Phase 3 $2.36B 8
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $224M 4
BBOT BridgeBio Oncology Therapeutics Oncology 2 Phase 1 $156M 6
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
CTMX CytomX Therapeutics Oncology 1 Phase 1 $423M 7
EIKN Eikon Therapeutics Oncology 2 Phase 2 $279M 13
ELTX Elicio Therapeutics Oncology 2 Phase 2 $40.5M 6
ERAS Erasca Oncology 1 Phase 1 $4.87B 5
IDYA IDEAYA Biosciences Oncology 1 NDA Submitted $2.65B 15
IMRX Immuneering Oncology 1 Phase 3 $224M 5
IBRX ImmunityBio Infectious DiseaseOncology 2 Approved $6.66B 17
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
LEGN Legend Biotech Oncology Rare 1 Approved $3.12B 17
MRKR Marker Therapeutics Oncology 1 Phase 1 $14.0M 5
MBRX Moleculin Biotech Oncology 1 Phase 2 $7.3M 9
NBP NovaBridge Biosciences OncologyOphthalmology 1 Phase 2 $95.4M 7
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
RVMD Revolution Medicines Oncology 2 Approved $35.2B 11
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9
TNGX Tango Therapeutics Oncology 1 Phase 1 $3.75B 5
VSTM Verastem Oncology 2 Approved $934M 5
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28